Oxford Immunotec Global PLC (NASDAQ:OXFD)’s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $13.41 and traded as high as $13.79. Oxford Immunotec Global shares last traded at $13.74, with a volume of 2,618 shares traded.
OXFD has been the topic of a number of research reports. TheStreet cut Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research note on Monday, July 15th. Zacks Investment Research cut Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. ValuEngine upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, BidaskClub upgraded Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $18.00.
The firm has a market capitalization of $378.05 million, a price-to-earnings ratio of 27.18 and a beta of 0.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 13.35 and a quick ratio of 12.76. The firm has a 50 day moving average price of $13.42 and a 200-day moving average price of $15.20.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.07. The business had revenue of $19.60 million for the quarter, compared to analysts’ expectations of $19.32 million. Oxford Immunotec Global had a return on equity of 14.76% and a net margin of 208.48%. The company’s revenue for the quarter was up 17.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.25) earnings per share. Equities research analysts predict that Oxford Immunotec Global PLC will post -0.17 earnings per share for the current year.
In other news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $19.90, for a total value of $59,700.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.21% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its holdings in Oxford Immunotec Global by 34.9% in the second quarter. Tower Research Capital LLC TRC now owns 2,734 shares of the company’s stock valued at $37,000 after buying an additional 708 shares during the last quarter. Aperio Group LLC purchased a new position in Oxford Immunotec Global in the second quarter valued at $42,000. C M Bidwell & Associates Ltd. purchased a new position in Oxford Immunotec Global in the second quarter valued at $93,000. BNP Paribas Arbitrage SA increased its holdings in Oxford Immunotec Global by 59,988.9% in the first quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock valued at $93,000 after buying an additional 5,399 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Oxford Immunotec Global in the second quarter valued at $173,000. 91.38% of the stock is currently owned by hedge funds and other institutional investors.
About Oxford Immunotec Global (NASDAQ:OXFD)
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.